MS Briefs

Lower urinary tract dysfunction in patients with MS


 

Key clinical point: Higher Expanded Disability Status Scale (EDSS) score is associated with an unfavorable urologic course in patients with multiple sclerosis (MS), and increased postvoid residual volume (PVR) correlates with male gender, EDSS, and disease course.

Major finding: The presence of lower urinary tract symptoms (LUTS) was more frequently associated with a primary progressive disease course ( P = .040), a higher level of disability (mean EDSS of 6.4, P = .011), and urinary tract infection ( P = .002). PVR values were higher in patients with LUTS vs. those without ( P = .011). Increased PVR correlated with male gender ( P less than .001), EDSS score ( P = .005), and disease course ( P = .041). Higher PVR correlated with incontinence ( P = .007), chronic urinary retention ( P less than .001), incomplete emptying ( P = .015), and diminished stream intensity ( P = .040).

Study details: The findings are based on a study of 501 patients with clinically definite MS (68.9% females; mean age: 56.0 ± 12.3 years).

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Citation: Monti Bragadin M et al. Mult Scler Relat Disord. 2020 Jul 5. doi: 10.1016/j.msard.2020.102378.

Recommended Reading

MSBase study validates therapy for relapse in secondary progressive MS
ICYMI Multiple Sclerosis
Effect of hookworm treatment on relapsing MS
ICYMI Multiple Sclerosis
Study suggests potential prognostic value of enlarged perivascular spaces in MS
ICYMI Multiple Sclerosis
MS: Rituximab effective in controlling disability and relapse rates
ICYMI Multiple Sclerosis
Risk factors for severe COVID-19 in MS patients
ICYMI Multiple Sclerosis
FDA approves ofatumumab (Kesimpta) for relapsing forms of MS
ICYMI Multiple Sclerosis
High-dose biotin treatment tied to increased risk of relapse in progressive MS
ICYMI Multiple Sclerosis
Secondary progressive MS: Sustained immunotherapy may improve disability outcomes
ICYMI Multiple Sclerosis
Personalized extended interval dosing does not reduce efficacy of natalizumab in MS
ICYMI Multiple Sclerosis
Efficacy of disease-modifying therapies in treatment-naïve patients with MS
ICYMI Multiple Sclerosis